Astellas Pharma Inc. entered into an agreement to acquire Propella Therapeutics, Inc. for approximately $175 million. The transaction is expected to occur during Astellas’ fiscal year 2023 ending March 31, 2024. Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. PRL-02 is a novel, long-acting prodrug of abiraterone that, following intramuscular injection, is expected to achieve hig...